// App-Quantinova.ai

: Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

Researchers

Presenter

  • Richard S. Finn

Principal Investigators

  • Masafumi Ikeda

  • Heinz-Josef Klümpen

  • Gianluca Masi

  • Alessandro Granito

  • Ho Yeong Lim

  • Masatoshi Kudo

  • Shukui Qin

  • René Gerolami

  • Yi-Hsiang Huang

  • Do Young Kim

  • Matthias Pinter

  • Naoya Kato

  • Masayuki Kurosaki

  • Kazushi Numata

  • Javeed Khan

  • Kirhan Ozgurdal

  • Yoon Jun Kim

Medical Centers

  • Bayer, Reading, United Kingdom.

  • Niigata University School of Medicine, Niigata, Japan

  • Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital

  • Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China

  • Univeristy of Bologna, Bologna, Italy

  • Severance Hospital, Seoul, Korea

  • Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France

  • Chiba University Hospital, Chiba, Japan

  • CHU La Timone, Marseille, France

  • Seoul National University Hospital, Seoul, Korea

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • National Cancer Center, EPOC, Chiba, Japan

  • Yokohama City University Medical Center, Yokohama City, Japan

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Medical University of Vienna, Vienna, Austria

  • David Geffen School of Medicine at UCLA, Revlon/UCLA Breast Center, Long Beach, CA

  • Musashino Red Cross Hospital, Tokyo, Japan

  • Bayer Consumer Care AG, Basel, Switzerland

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

Locations

  • United Kingdom

  • Republic of South Korea

  • United States

  • Netherlands

  • Italy

  • Austria

  • Switzerland

  • China

  • Taiwan

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Regenerating islet-derived 1 alpha

Drug/Treatment

  • Regorafenib

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT03289273

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved